<unk>  is a von Willebrand factor (vWF)-directed antibody fragment that is FDA approved for the treatment of adult patients with acquired thrombotic thrombocytopenia purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.   Common adverse reactions include epistaxis, headache, and gingival bleeding.
Caplacizumab
Ixekizumab
Bococizumab
Risankizumab
Tocilizumab
Mogamulizumab
Atezolizumab
Emicizumab